Aberrant expression of the apoptosis-related proteins BAK and MCL1 in T cells in multiple sclerosis

Journal of Neuroimmunology

Volumn 244, Issue 1-2, 2012, Pages 51-56

  Mandel, Ilana ^a   Paperna, Tamar ^a   Miller, Ariel ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

Apoptosis; Autoimmune; BAK; MCL1; Multiple sclerosis; Proteasome

Indexed keywords

BETA INTERFERON; PROTEIN BAK; PROTEIN MCL 1; RNA; UBIQUITIN PROTEIN LIGASE E3;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; RELAPSE; REMISSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES; UBIQUITIN-PROTEIN LIGASES; YOUNG ADULT;

EID: 84857924381     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.12.026     Document Type: Article

References (59)

1. Chan A., Weilbach F.X., Toyka K.V., Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin. Exp. Immunol. 2005, 139:152-158.
2. Clohessy J.G., Zhuang J., de Boer J., Gil-Gomez G., Brady H.J. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J. Biol. Chem. 2006, 281:5750-5759.
3. Comi C., Leone M., Bonissoni S., DeFranco S., Bottarel F., Mezzatesta C., Chiocchetti A., Perla F., Monaco F., Dianzani U. Defective T cell fas function in patients with multiple sclerosis. Neurology 2000, 55:921-927.
4. Cuconati A., Mukherjee C., Perez D., White E. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 2003, 17:2922-2932.
5. Dalla Libera D., Di Mitri D., Bergami A., Centonze D., Gasperini C., Grasso M.G., Galgani S., Martinelli V., Comi G., Avolio C., Martino G., Borsellino G., Sallusto F., Battistini L., Furlan R. T regulatory cells are markers of disease activity in multiple sclerosis patients. PLoS One 2011, 6:e21386.
6. Danke N.A., Koelle D.M., Yee C., Beheray S., Kwok W.W. Autoreactive T cells in healthy individuals. J. Immunol. 2004, 172:5967-5972.
7. Dhib-Jalbut S., Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010, 74(Suppl 1):S17-S24.
8. Dunkle A., Dzhagalov I., He Y.W. Cytokine-dependent and cytokine-independent roles for Mcl-1: genetic evidence for multiple mechanisms by which Mcl-1 promotes survival in primary T lymphocytes. Cell Death Dis. 2011, 2:e214.
9. Dunkle A., He Y.W. Apoptosis and autophagy in the regulation of T lymphocyte function. Immunol. Res. 2011, 49:70-86.
10. Dzhagalov I., Dunkle A., He Y.W. The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages. J. Immunol. 2008, 181:521-528.
11. Frisullo G., Nociti V., Iorio R., Patanella A.K., Caggiula M., Marti A., Sancricca C., Angelucci F., Mirabella M., Tonali P.A., Batocchi A.P. Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients. Immunology 2009, 127:418-428.
12. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 2001, 50:443-451.
13. Gillissen B., Wendt J., Richter A., Richter A., Muer A., Overkamp T., Gebhardt N., Preissner R., Belka C., Dorken B., Daniel P.T. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J. Cell Biol. 2010, 188:851-862.
14. Hebb A.L., Moore C.S., Bhan V., Campbell T., Fisk J.D., Robertson H.A., Thorne M., Lacasse E., Holcik M., Gillard J., Crocker S.J., Robertson G.S. Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. Mult. Scler. 2008, 14:577-594.
15. Hebb A.L., Moore C.S., Bhan V., Robertson G.S. Targeting apoptosis to treat multiple sclerosis. Curr. Drug Discov. Technol. 2008, 5:75-77.
16. Hemmer B., Nessler S., Zhou D., Kieseier B., Hartung H.P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2006, 2:201-211.
17. Hirotani M., Niino M., Sasaki H. The role of B cells in multiple sclerosis: implications for B-cell-targeted therapy. Curr. Med. Chem. 2010, 17:3215-3222.
18. Huang W.X., Huang M.P., Gomes M.A., Hillert J. Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 2000, 55:928-934.
19. Hur E.M., Youssef S., Haws M.E., Zhang S.Y., Sobel R.A., Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat. Immunol. 2007, 8:74-83.
20. Inuzuka H., Shaik S., Onoyama I., Gao D., Tseng A., Maser R.S., Zhai B., Wan L., Gutierrez A., Lau A.W., Xiao Y., Christie A.L., Aster J., Settleman J., Gygi S.P., Kung A.L., Look T., Nakayama K.I., DePinho R.A., Wei W. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011, 471:104-109.
21. Kurne A., Guc D., Canpinar H., Aydin O.F., Sayat G., Yorubulut M., Esendagli G., Karabudak R. Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy. Acta Neurol. Scand. 2011, 123:8-12.
22. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
23. Liu H., Huang Q., Shi B., Eksarko P., Temkin V., Pope R.M. Regulation of Mcl-1 expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum. 2006, 54:3174-3181.
24. Liu X., Leung S., Wang C., Tan Z., Wang J., Guo T.B., Fang L., Zhao Y., Wan B., Qin X., Lu L., Li R., Pan H., Song M., Liu A., Hong J., Lu H., Zhang J.Z. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat. Med. 2010, 16:191-197.
25. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
26. Maurer U., Charvet C., Wagman A.S., Dejardin E., Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 2006, 21:749-760.
27. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
28. Opferman J.T., Korsmeyer S.J. Apoptosis in the development and maintenance of the immune system. Nat. Immunol. 2003, 4:410-415.
29. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
30. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13:227-231.
31. Rathmell J.C., Lindsten T., Zong W.X., Cinalli R.M., Thompson C.B. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat. Immunol. 2002, 3:932-939.
32. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., le Page E., Edan G., McDonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Sorensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sa M., Salemi G., Savettieri G., Hillert J., Compston D.A. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151.
33. Seidi O.A., Sharief M.K. The expression of apoptosis-regulatory proteins in B lymphocytes from patients with multiple sclerosis. J. Neuroimmunol. 2002, 130:202-210.
34. Semra Y.K., Seidi O.A., Sharief M.K. Disease activity in multiple sclerosis correlates with T lymphocyte expression of the inhibitor of apoptosis proteins. J. Neuroimmunol. 2002, 122:159-166.
35. Sharief M.K. Impaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis. J. Neuroimmunol. 2000, 109:236-243.
36. Sharief M.K., Douglas M., Noori M., Semra Y.K. The expression of pro- and anti-apoptosis Bcl-2 family proteins in lymphocytes from patients with multiple sclerosis. J. Neuroimmunol. 2002, 125:155-162.
37. Sharief M.K., Matthews H., Noori M.A. Expression ratios of the Bcl-2 family proteins and disease activity in multiple sclerosis. J. Neuroimmunol. 2003, 134:158-165.
38. Sharief M.K., Noori M.A., Zoukos Y. Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-beta therapy. J. Neuroimmunol. 2002, 129:224-231.
39. Sharief M.K., Semra Y.K. Upregulation of the inhibitor of apoptosis proteins in activated T lymphocytes from patients with multiple sclerosis. J. Neuroimmunol. 2001, 119:350-357.
40. Sharief M.K., Semra Y.K., Seidi O.A., Zoukos Y. Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J. Neuroimmunol. 2001, 120:199-207.
41. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007, 13:139-145.
42. Stewart D.P., Koss B., Bathina M., Perciavalle R.M., Bisanz K., Opferman J.T. Ubiquitin-independent degradation of antiapoptotic MCL-1. Mol. Cell. Biol. 2010, 30:3099-3110.
43. Strasser A. The role of BH3-only proteins in the immune system. Nat. Rev. Immunol. 2005, 5:189-200.
44. Takeuchi O., Fisher J., Suh H., Harada H., Malynn B.A., Korsmeyer S.J. Essential role of BAX. BAK in B cell homeostasis and prevention of autoimmune disease. Proc. Natl Acad. Sci. U. S. A. 2005, 102:11272-11277.
45. Thangarajh M., Masterman T., Rot U., Duvefelt K., Brynedal B., Karrenbauer V.D., Hillert J. Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J. Neuroimmunol. 2005, 167:210-214.
46. Thomas L.W., Lam C., Edwards S.W. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010, 584:2981-2989.
47. Tischner D., Reichardt H.M. Glucocorticoids in the control of neuroinflammation. Mol. Cell. Endocrinol. 2007, 275:62-70.
48. Todaro M., Zeuner A., Stassi G. Role of apoptosis in autoimmunity. J. Clin. Immunol. 2004, 24:1-11.
49. Venken K., Hellings N., Thewissen M., Somers V., Hensen K., Rummens J.L., Medaer R., Hupperts R., Stinissen P. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2008, 123:79-89.
50. Vikstrom I., Carotta S., Luthje K., Peperzak V., Jost P.J., Glaser S., Busslinger M., Bouillet P., Strasser A., Nutt S.L., Tarlinton D.M. Mcl-1 is essential for germinal center formation and B cell memory. Science 2010, 330:1095-1099.
51. von Boehmer H., Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat. Immunol. 2010, 11:14-20.
52. Waiczies S., Weber A., Lunemann J.D., Aktas O., Zschenderlein R., Zipp F. Elevated Bcl-X(L) levels correlate with T cell survival in multiple sclerosis. J. Neuroimmunol. 2002, 126:213-220.
53. Warr M.R., Shore G.C. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr. Mol. Med. 2008, 8:138-147.
54. Willis S.N., Chen L., Dewson G., Wei A., Naik E., Fletcher J.I., Adams J.M., Huang D.C. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19:1294-1305.
55. Zang Y.C., Kozovska M.M., Hong J., Li S., Mann S., Killian J.M., Rivera V.M., Zhang J.Z. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur. J. Immunol. 1999, 29:1692-1700.
56. Zhang F., Shi Y., Wang L., Sriram S. Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PLoS One 2011, 6:e16795.
57. Zhong Q., Gao W., Du F., Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005, 121:1085-1095.
58. Zipp F. Apoptosis in multiple sclerosis. Cell Tissue Res. 2000, 301:163-171.
59. Zipp F., Wendling U., Beyer M., Grieger U., Waiczies S., Wagenknecht B., Haas J., Weller M. Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells. J. Neuroimmunol. 2000, 110:214-222.